Danske Bank A S boosted its holdings in shares of Medtronic PLC (NYSE:MDT – Free Report) by 3.6% in the third quarter, according to its most recent filing with the SEC. The firm owned 744,120 shares of the medical technology company’s stock after acquiring an additional 25,961 shares during the period. Danske Bank A S’s holdings in Medtronic were worth $64,210,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Diversified Trust Co boosted its holdings in Medtronic by 14.6% during the third quarter. Diversified Trust Co now owns 115,378 shares of the medical technology company’s stock worth $9,956,000 after buying an additional 14,720 shares during the last quarter. EagleClaw Capital Managment LLC grew its position in shares of Medtronic by 5.2% during the 3rd quarter. EagleClaw Capital Managment LLC now owns 71,390 shares of the medical technology company’s stock worth $6,160,000 after buying an additional 3,545 shares during the period. Moors & Cabot Inc. grew its position in shares of Medtronic by 10.3% during the 3rd quarter. Moors & Cabot Inc. now owns 68,621 shares of the medical technology company’s stock worth $5,921,000 after buying an additional 6,388 shares during the period. Valmark Advisers Inc. increased its stake in shares of Medtronic by 2.1% in the 3rd quarter. Valmark Advisers Inc. now owns 5,758 shares of the medical technology company’s stock valued at $497,000 after acquiring an additional 121 shares during the last quarter. Finally, Money Concepts Capital Corp increased its stake in shares of Medtronic by 0.4% in the 3rd quarter. Money Concepts Capital Corp now owns 55,424 shares of the medical technology company’s stock valued at $4,783,000 after acquiring an additional 243 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.
Analysts Set New Price Targets
Several brokerages have commented on MDT. Wells Fargo & Company upped their target price on shares of Medtronic from $102.00 to $104.00 and gave the company an “overweight” rating in a research note on Wednesday, September 2nd. Deutsche Bank reissued a “hold” rating and set a $92.00 price target on shares of Medtronic in a research report on Thursday, September 3rd. Bank of America boosted their price target on shares of Medtronic from $95.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, September 2nd. Robert W. Baird boosted their price target on shares of Medtronic from $91.00 to $100.00 and gave the company a “neutral” rating in a report on Wednesday, September 2nd. Finally, Weiss Ratings upgraded shares of Medtronic from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, October 19th. Eighteen research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $102.88.
Read Our Latest Stock Analysis on Medtronic
Insider Buying and Selling
In related news, CEO Geoffrey Martha sold 50,000 shares of the business’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $95.00, for a total value of $4,750,000.00. Following the sale, the chief executive officer directly owned 277,866 shares of the company’s stock, valued at approximately $26,397,270. The trade was a 15.25% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Marinaro sold 10,420 shares of the business’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $96.00, for a total transaction of $1,000,320.00. Following the completion of the sale, the executive vice president directly owned 105,916 shares in the company, valued at $10,167,936. This represents a 8.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 61,903 shares of company stock worth $5,889,203 over the last ninety days. Company insiders own 0.27% of the company’s stock.
Medtronic Stock Performance
Shares of MDT stock opened at $102.84 on Monday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.54 and a current ratio of 2.07. The company has a market capitalization of $131.54 billion, a P/E ratio of 25.33, a price-to-earnings-growth ratio of 2.41 and a beta of 0.56. The company’s 50 day moving average price is $93.72 and its two-hundred day moving average price is $88.47. Medtronic PLC has a 52 week low of $73.31 and a 52 week high of $106.33.
Medtronic (NYSE:MDT – Get Free Report) last released its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.39 by $0.06. The company had revenue of $9.76 billion during the quarter, compared to analysts’ expectations of $9.55 billion. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The business’s quarterly revenue was up 13.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, analysts expect that Medtronic PLC will post 5.98 earnings per share for the current fiscal year.
Medtronic Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Friday, October 16th. Investors of record on Friday, September 25th were issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date was Friday, September 25th. Medtronic’s dividend payout ratio (DPR) is presently 70.94%.
Medtronic Profile
Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.
Further Reading
- Five stocks we like better than Medtronic
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
